STAT5A and prolymphocytic leukemia: Combination strategies with agents like cladribine, azacytidine, and venetoclax further enhance efficacy, even in low-responding cases, highlighting dual STAT3/STAT5 inhibition as a promising therapeutic approach in T-PLL.